| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 04/03/2002 | CN1343219A Substituted phenethylamine derivatives |
| 04/03/2002 | CN1343174A 计量阀 Metering valve |
| 04/03/2002 | CN1342482A Chinese patent medicine for treating nenoxenia |
| 04/02/2002 | US6365775 Biphenyl compounds and their use as oestrogenic agents |
| 04/02/2002 | US6365664 Gels formed by the interaction of poly(aldehyde) with various substances |
| 04/02/2002 | US6365609 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 03/29/2002 | WO2003045398A1 Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof |
| 03/28/2002 | WO2002025194A1 Drying method for selectively removing volatile components from wet coatings |
| 03/28/2002 | WO2002024924A2 Protein phosphatases |
| 03/28/2002 | WO2002024923A1 Polypeptide having phospholipase a2 actiivty |
| 03/28/2002 | WO2002024891A2 B7-like molecules and uses thereof |
| 03/28/2002 | WO2002024726A2 Olfactory and pheromones g-protein coupled receptors |
| 03/28/2002 | WO2002024715A2 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 03/28/2002 | WO2002024703A1 Bicyclic heteroaromatic compounds |
| 03/28/2002 | WO2002024702A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | WO2002024641A1 Tricyclic indole compounds having affinity for serotonin receptor |
| 03/28/2002 | WO2002024633A1 Phenylpropionic acid derivatives |
| 03/28/2002 | WO2002024219A1 Growth factor complex |
| 03/28/2002 | WO2002024214A2 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 03/28/2002 | WO2002024180A2 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 03/28/2002 | WO2001089479A3 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 03/28/2002 | WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 03/28/2002 | WO2001039758A3 Method for the treatment and/or prophylaxis of diseases caused by il-12 using thalidomide and anti-inflammatory cytokine |
| 03/28/2002 | US20020037915 4-(4-(1- phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5-methylthiothiophene-2 -carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases |
| 03/28/2002 | US20020037895 Wherein the lactone ring is modified; preventing or treating disorders or diseases mediated by LFA-1 (Leukocyte Function-associated Antigen-1) ICAM-1 (intercellular adhesion molecules) interactions; autoimmune disorders, inflammation |
| 03/28/2002 | US20020037861 Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X |
| 03/28/2002 | US20020037850 Genetic engineering; binding to antibodies |
| 03/28/2002 | US20020037836 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| 03/28/2002 | US20020037555 Human glucose-6-phosphatase molecules and uses thereof |
| 03/28/2002 | US20020037533 A compound that is a Prolactin Releasing Peptide receptor (PrRP) agonist; determining the ability of the compound to promote wakefulness; providing a PrRP receptor antagonist and determining the ability of the compound to promote sleep |
| 03/28/2002 | US20020037311 Transdermal delivery of lasofoxifene |
| 03/28/2002 | DE10043457A1 Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen A method for the treatment of schizophrenia and related psychoses, and the use of erythropoietin for the treatment or Erythropoietinderivaten of schizophrenia and related psychoses |
| 03/28/2002 | DE10043321A1 Transdermales therapeutisches System Transdermal therapeutic system |
| 03/28/2002 | CA2424394A1 Growth factor complex comprising an insulin-like growth factor binding protein bound to vitronectin |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2423058A1 Polypeptide having phospholipase a2 activity |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421865A1 Olfactory and pheromones g-protein coupled receptors |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/28/2002 | CA2357853A1 Use of growth hormone secretagogues in conjunction with physical exercise |
| 03/27/2002 | EP1190086A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 03/27/2002 | EP1190065A2 Atp binding cassette transporter protein abc1 polypeptides |
| 03/27/2002 | EP1190059A1 Sgip peptides |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1189942A1 Somatostatin agonists |
| 03/27/2002 | EP1189941A1 Neuromedin b and somatostatin receptor agonists |
| 03/27/2002 | EP1189931A2 Peptide compounds that bind her2 |
| 03/27/2002 | EP1189895A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 03/27/2002 | EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS |
| 03/27/2002 | EP1189629A2 Methods and reagents for treating glucose metabolic disorders |
| 03/27/2002 | EP1189620A1 Formulation comprising testosteron undecanoate and castor oil |
| 03/27/2002 | EP1189619A1 Administration of non-oral androgenic steroids to women |
| 03/27/2002 | EP1189583A1 Indole derivatives |
| 03/27/2002 | EP0873336B1 Antagonists of gonadotropin releasing hormone |
| 03/27/2002 | EP0730470B1 Improved interferon polymer conjugates |
| 03/27/2002 | CN1342166A GLP-1 analogues |
| 03/27/2002 | CN1342143A N-substituted indolines as estrogenic agents |
| 03/27/2002 | CN1342068A Core tablet for controlled release of gliclazide after oral administration |
| 03/27/2002 | CN1341588A Intermediate product for preparing substituted 2,4-thiazolidine diketone derivative |
| 03/26/2002 | US6362231 Calcium receptor active compounds |
| 03/26/2002 | US6362211 Polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 03/26/2002 | US6361997 Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy |
| 03/26/2002 | US6361938 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 03/26/2002 | US6361776 Polypeptide isolated from mycobacterium vaccae comprising specified amino acid sequence, capable of eliciting and/or enhancing immune response to heterologous antigen |
| 03/26/2002 | US6361768 Hydrophilic ampholytic polymer |
| 03/21/2002 | WO2002023184A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | WO2002022851A2 Novel tumor-associated marker |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022647A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids |
| 03/21/2002 | WO2002022645A2 Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity |
| 03/21/2002 | WO2002022642A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022599A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022592A2 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | WO2002022585A1 Tetrahydroquinoline compounds |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022154A2 Pharmaceutical compositions for sustained drug delivery |
| 03/21/2002 | WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| 03/21/2002 | WO2002022132A2 Novel topical oestroprogestational compositions with systemic effect |
| 03/21/2002 | WO2002022110A2 Contraception process and administration form for the same |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001060991A3 Human kinases |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001051055A3 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 03/21/2002 | US20020035735 Reproducing and animal; obtain preferential embryonic cells, culture cells, transfer cells to primate, recover infant |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |